Equities Research Analysts’ Updated EPS Estimates for January 13th (BEAM, BIIB, CNR, COGT, CRR.UN, ENFN, EXAS, HOLX, IGMS, IMNM)

Equities Research Analysts’ updated eps estimates for Monday, January 13th:

Beam Therapeutics (NASDAQ:BEAM) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $57.00 target price on the stock.

Biogen (NASDAQ:BIIB) had its outperform rating reiterated by analysts at William Blair.

Canadian National Railway (TSE:CNR) (NYSE:CNI) was upgraded by analysts at TD Securities from a hold rating to a buy rating. They currently have C$170.00 price target on the stock, down from their previous price target of C$175.00.

Cogent Biosciences (NASDAQ:COGT) had its neutral rating reissued by analysts at Wedbush. The firm currently has a $11.00 price target on the stock.

Crombie Real Estate Investment Trust (TSE:CRR.UN) was upgraded by analysts at Raymond James from an outperform rating to a strong-buy rating. The firm currently has C$16.75 price target on the stock, down from their previous price target of C$17.25.

Enfusion (NYSE:ENFN) had its market perform rating reaffirmed by analysts at William Blair.

Exact Sciences (NASDAQ:EXAS) had its outperform rating reiterated by analysts at William Blair.

Hologic (NASDAQ:HOLX) had its outperform rating reaffirmed by analysts at William Blair.

IGM Biosciences (NASDAQ:IGMS) was upgraded by analysts at JPMorgan Chase & Co. from an underweight rating to a neutral rating.

Immunome (NASDAQ:IMNM) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $33.00 price target on the stock.

Nuvalent (NASDAQ:NUVL) had its outperform rating reissued by analysts at Wedbush. They currently have a $115.00 price target on the stock.

ORIC Pharmaceuticals (NASDAQ:ORIC) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $20.00 price target on the stock.

SpringWorks Therapeutics (NASDAQ:SWTX) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $77.00 target price on the stock.

Spyre Therapeutics (NASDAQ:SYRE) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $65.00 price target on the stock.

Vertex Pharmaceuticals (NASDAQ:VRTX) had its outperform rating reaffirmed by analysts at William Blair.